The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer ... than shots made using traditional cell culture or recombinant techniques.

Nov. 25, 2022 — An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, and thus might ...

"The issues with the kind of influenza vaccines that we have is that they do not lead to long-term protection in these specific strains of influenza." He adds that for the most at-risk populations ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

[6] It had undergone a very long adaptation process involving 77 passages in mice; 717 passages in cell culture ... for the composition of influenza vaccines, based on worldwide surveillance ...

Scott, MD, a Louisville, Kentucky-based otolaryngologist ... is needed for avian flu prevention,” Dr. Scott added. 90695: Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted for ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

The H5N1 "bird flu ... reactive T cell responses may already be in place and may help decrease disease severity," says Sette, who also serves as Co-Director of the LJI Center for Vaccine Innovation.

Wisconsin is entering the fall on the heels of a severe flu season last year and as vaccine rates for the virus continue to drop statewide. Here's what to know about the flu vaccine in Wisconsin ...